Arch Oncology

Arch Oncology is a privately held clinical-stage immuno-oncology company dedicated to the discovery and development of first-class antibody therapies for the treatment of cancer patients. The next-generation CD47 antibodies from Arch Oncology are highly differentiated, with the potential to improve safety and efficacy compared to other drugs in this class. The focus of oncology is on discovering and developing new antibody therapies with the greatest potential for treating cancer patients. The next-generation antibodies in oncology are highly differentiated, with the potential to enhance their safety and efficacy compared to similar drugs.